A multicenter, randomized, double-blind, placebo-controlled, phase II study to evaluate the efficacy and safety of Hemay005 tablet in the treatment of moderate to severe atopic dermatitis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
79
A PDE-4 inhibitor
First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
EASI-75
Percentage of subjects reaching 75% or higher improvement from baseline
Time frame: week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.